A Powerful Pipeline of Revolutionary Technology
Has The Potential To Take This NASDAQ Opportunity From
A 52 Week Low of 0.77 to its 10.00 Target
INTRODUCING NASDAQ: CTXR
CURRENT SENTIMENT ON BARCHART.COM IS STRONG BUY BASED ON 3 ANALYSTS RATINGS
- Weekly average price is: $1.33 (As Of 03/07/23)
- 50-day moving average at $1.18
- 200-day moving average at $1.52
- 20-day exponential moving average $1.07 (first line of resistance)
- Dawson James Analyst Jason Kolberts projects a’ $10.00 target
A POTENTIAL 1,189% Upside May Be Possible for Today’s Breakout Alert
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products.
The company’s massive upside potential lies in its pipeline of products that target a range of indications, including anti-infectives, cancer care, pain management, and critical care.
The prospect of the company’s product pipeline, based on the potential ability to bring these products to market successfully, is garnering interest in the investment community.
Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. The American Cancer Society’s estimates for non-Hodgkin lymphoma in 2023 are: About 80,550 people (44,880 males and 35,670 females) will be diagnosed with NHL.14
NASDAQ:CTXR has acquired the rights to the experimental compound E-7777 – an improved experimental compound based on a previously FDA approved drug therapy that attacs cancer cells, and may be months away from its own FDA approval, providing a new alternative to the current radio/chemotherapy approach to attacking non-hodgkins lymphoma.
This is a potential game-changer within a 3.5 BN Market
ying well under the radar, Citius Pharmaceuticals (NSDQ: CTXR) has quietly acquired the rights to the experimental compound “E-7777,” a direct improvement to a previously FDA-approved medication that directly attacks infected cancer cells inside the human body.
And this new cancer-fighting remedy could be mere months away from its own approval.
If and when it hits the market, this new treatment could provide a whole new proven alternative to the harsh side effects of chemotherapy or aggressive radiation treatment.
Directly targeting and attacking infected cells, E-7777 could transform the $3.5 Billion market for Non-Hodgkin’s Lymphoma treatment. The anticipated PDUFA action date is July 28, 2023.
The best part of this whole story? This is just one of several potentially game-changing new therapies in the company’s pipeline …
Factors that investors may consider when evaluating Citius Pharmaceuticals, Inc. as an investment opportunity include the company’s financial performance, the strength of its management team, its competitive position within the industry, and the potential market size and demand for its products.
Why Invest In NASDAQ:CTXR?
- A Diversified pipeline of potential first-in-class (in development) products with multiple near-term staged catalysts
- Several attractive multi-billion-dollar potentials in adjunctive cancer, infectious disease, and gastrointestinal disease care
- Robust research partnerships with the potential to rapidly advance the product pipeline
- A strong balance sheet, showing the fiscal ability to further pipeline development and invest in long-term growth
- An experienced leadership team with a highly successful track record
Investment in cancer care and pain management is important because both are significant medical issues that affect a large portion of the population. As we all know, cancer is a complex and unequivocally devastating disease that can cause significant physical, emotional, and financial distress for patients and their families. Pain, both acute and chronic, can also have a significant impact on quality of life and can lead to disability, depression, and other complications.
Key Highlights
Analyst Target
- Dawson James Analyst Jason Kolbert gave NASDAQ:CTXR a $10.00 target, meaning a potential l upside of 1,198% following a 52-week low of $.77 6
Active Chart:
- Following NASDAQ:CTXR’s 52-week low of $.77, shares have climbed to $1.03 for a solid 34.76% 30 day move, and trending upwards.7
FDA Confirmation
- NASDAQ:CTXR reported that the FDA confirmed the Prescription Drug User Fee Act (PDUFA) target action date of July 28, 2023.8
Phase 3 Trial
- Citius Pharmaceuticals, Inc. completed the Phase 3 trial of a cancer immunotherapy product for the treatment of persistent or recurrent cutaneous T-cell lymphoma and submitted a biologics license application to the U.S. FDA.9
Accelerated Advancement:
- The company expanded and accelerated its Phase 3 Mino-Lok trial to additional sites outside the United States.
- If approved, Mino-Lok will be the first in line, premier antibiotic lock solution with FDA-approval, capable of salvaging infected central venous catheters that cause catheter-related bloodstream infections (the prolificness of which we will expand on later.)
Clinical Collaboration:
- NASDAQ: CTXR collaborated with the University of Pittsburgh to evaluate regulatory T-cell depletion with its immunotherapy product (I/ONTAK (E7777)) in combination with pembrolizumab in recurrent or metastatic solid cancer tumors in a Phase 1 investigator-initiated trial, with first patient enrolled in November 2022.10
Investment in cancer care can help to improve treatment options for patients, develop new therapies and drugs, and ultimately improve survival rates and quality of life for those affected by the disease. .
From an investment perspective, how do we effectively measure the value potential of this tremendously important biomedical space?
Starting with a basic understanding of the market space…
The critical care products market size varies depending on the specific product category, region, and other factors. However, according to a report by Grand View Research published in 2021, the global critical care products market size was valued at USD 34.1 billion in 2020 and is expected to grow at a CAGR of 6.4% from 2021 to 2028.1
Factors driving the growth of the critical care products market include the increasing prevalence of chronic diseases, growing demand for advanced treatment options, and rising healthcare expenditure.
Within these parameters, it is an unequivocal reality that oncology based critical care products and pain management initiatives have a paramount position within the healthcare space, and unfortunately will remain necessary for the foreseeable future.
Central venous catheters (CVCs) are a common medical device used in critical care settings, but they are also associated with a risk of infection. Here are some statistics related to CVC infections:
- CVC-associated bloodstream infections (CVC-BSIs) are estimated to affect 250,000 patients in the US each year.2
- CVC-BSIs are associated with an increased risk of mortality, with one study reporting a mortality rate of 12.5% among patients with CVC-BSIs.3
- The incidence of CVC-BSIs varies depending on the type of CVC and the setting in which it is used, but studies have reported rates ranging from 0.5 to 7.6 per 1,000 catheter-days.4
- The cost of treating CVC-BSIs can be significant, with one study estimating that the average cost per episode of CVC-BSI was $45,814 in 2015 (source: Journal of Critical Care).5
What’s In The Pipeline?
Citius Pharmaceuticals’ lead product candidate is Mino-Lok, which is a combination of antimicrobial agents designed to treat and salvage infected central venous catheters.
Based on the current statistical analysis above, this technology will not only prevent discomfort, illness, and potentially fatal outcomes, it also has the potential to save millions of dollars in healthcare costs each year.
We’re Talking $7.2 Billion in Potential Market Disruption
Mino-Lock could potentially eradicate Catheter-Related Bloodstream Infections, preventing unnecessary and costly surgeries, and revolutionizing treatment of a $1.5 Billion problem that is currently draining the medical system.
Combined with a full pipeline of other treatments, Citius Pharmaceuticals could be sitting on top of $5.5 Billion in cumulative pharmaceutical market disruption…
With a cash float through Dec 2023, only ONE PRODUCT in the company’s pipeline needs to show success or make it to market.
NASDAQ:CTXR is a company that needs to be at the TOP of your watchlist, and Mino-Lock is already showing huge potential.
The company is developing other products in the anti-infective space, including Hydro-Lido, which is a topical formulation for the treatment of hemorrhoids, and Mino-Wrap, which is a topical gel for the prevention of infections associated with surgical implants.
In addition to its anti-infective products, Citius Pharmaceuticals is developing products in the oncology and stem cell therapy spaces. The company’s CITI-002 product is a novel therapeutic agent that is being developed for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients. Citius Pharmaceuticals is also developing a stem cell therapy product called NoveCite, which is designed to treat acute myocardial infarction (AMI) and chronic heart failure (CHF).
NASDAQ:CTXR’s “Mino-Wrap” Has The Potential To Revolutionize The $400 Million
Post-Mastectomy Infection Prevention Market
- The Mino-Wrap has the potential to be the first and only FDA-approved product to prevent infections associated with post-mastectomy breast implants
- At the time of this writing, the product is in clinical development stages
- NASDAQ:CTXR is partnered with The University of Texas MD Anderson Cancer Center for the clinical stage of this product development
The Mino-Wrap’s intended application is to assist in post-operative infection reduction, for infections associated with surgical implants.
The global breast implants market size was valued at USD 2.20 billion in 2022. It is projected to reach USD 4.68 billion by 2031, growing with a CAGR of 7.8% during the forecast period (2023–2031)11
.
The Hemorrhoid Treatment Device Market
Is Expected To Reach $1.2 B USD Bn By 203112
Market research suggests that advancements in radiofrequency ablation therapies, as well as an increased emphasis on improving the effectiveness of combination therapies will increase future market outlook on hemorrhoid treatment devices.
NASDAQ:CTXR is taking advantage of the fact that there are currently no FDA-approved prescription products for hemorrhoids, with halobetasol and lidocaine formulations in production that may well become a physician go-to product for the 25 million per annum applications in which similar, non regulated products, are currently being used.
The Process
NASDAQ: (CTXR) is a “late-stage biopharmaceutical” company, meaning that a highly-experienced management team purchases rights to the most promising new therapies, choosing to bring these products to market, or license them to larger pharmaceutical companies.
What does this mean?
The company leans on its well versed, experienced management team to find products in the research and development stage that show promise of coming to fruition.
These products have already completed the earlier stages of drug development, including preclinical research and clinical trials, and are now focused on being going to market.
Late-stage pharmaceutical companies typically have a pipeline of drugs in advanced stages of clinical development, with a significant amount of data to support their efficacy and safety
.
At this stage, the company’s focus is on completing the necessary clinical trials required for regulatory approval, manufacturing the drug at scale, and preparing for commercial launch.
A company like NASDAQ:CTXR, with a track record of successful drug development, strong presence in the healthcare industry, significant funding, and a strong management team, has massive potential for growth if even one of its products successfully goes to market.
Overall, Citius Pharmaceuticals is focused on developing and commercializing innovative products that address critical care needs in a variety of therapeutic areas.
The company’s pipeline of products has the potential to address significant unmet medical needs and improve patient outcomes in a range of clinical settings.
Investment in cancer care and pain management is also important from a societal perspective. These medical issues can lead to significant healthcare costs, including hospitalizations, surgeries, and ongoing medical care.
By investing in research and development, new therapies and treatments can be developed that are more effective, less invasive, and less expensive, ultimately benefiting patients, healthcare providers, and society as a whole.
The Full Picture In Ten Seconds Or Less
- A hefty pipeline of late stage pharmaceutical products with established potential, in profitable market spaces.
- An upward trend following a 0.77 52 week low
- A cash float to see projects through Dec 2023
- An experienced leadership team
- Several positive technical indicators with a Strong BUY rating
- FDA approvals and Phase 3 Trials in progress
- Clinical collaborations with esteemed partners
As always, conduct your own research and analysis, and consult a professional before making any investment decisions.
NASDAQ:CTXR has massive upside potential, and we suggest that you place this ticker at the TOP of your watchlist. You don’t want to miss out on this opportunity.
Happy Trading,
The Team at The Daily NASDAQ
Sources:
- https://www.globenewswire.com/en/news-release/2022/07/05/2474417/0/en/Critical-Care-Equipment-Market-to-Witness-Healthy-Growth-of-USD-9-07-Billion-by-2029-Industry-Trends-Size-Share-and-Growth-Analysis.html
- https://www.ncbi.nlm.nih.gov/books/NBK430891/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095065/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095065/
- https://open.alberta.ca/dataset/c7e3fc16-7aea-455c-96a1-20811a640b1a/resource/e4228898-4d60-4652-880e-b632c3282fb9/download/pmd-hospital-acquired-central-catheter-bsi-rate.pdf
- https://dawsonjames.com/wp-content/uploads/2022/12/CTXR.12.23.22_-final1.pdf
- https://www.barchart.com/stocks/quotes/CTXR/overview
- https://finance.yahoo.com/news/citius-pharmaceuticals-inc-reports-fiscal-213000115.html
- https://finance.yahoo.com/news/citius-pharmaceuticals-inc-reports-fiscal-213000115.html
- https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-a-clinical-collaboration-with-the-university-of-pittsburgh-to-evaluate-t-reg-cell-depletion-with-iontak-e7777-in-combination-with-pembrolizumab-in-recurrent-or-metastatic-solid-cancer-tumors-in–301631592.html
- https://www.globenewswire.com/en/news-release/2022/11/16/2557494
- https://ca.sports.yahoo.com/news/hemorrhoid-treatment-devices-market-exceed-130300100
- https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/key-statistics.html#:~:text=Non%2DHodgkin%20lymphoma%20(NHL),will%20be%20diagnosed%20with%20NHL.
- https://www.mordorintelligence.com/industry-reports/non-hodgkins-lymphoma-therapeutics-market#:~:text=The%20global%20non-Hodgkin%20lymphoma%20therapeutics%20market%20has%20been,due%20to%20increasing%20technological%20advancements%20in%20the%20region.
1189% Upside Potential for This BioPharma Powerhouse
